Paul Tudor Jones Keros Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 19,787 shares of KROS stock, worth $234,278. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,787
Previous 10,357
91.05%
Holding current value
$234,278
Previous $473,000
142.92%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding KROS
# of Institutions
177Shares Held
30.1MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$29.8 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$22.5 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$22 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$18 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$17.9 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $305M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...